<DOC>
	<DOCNO>NCT01386944</DOCNO>
	<brief_summary>The objective ass effect Neupro® severity Restless Leg Syndrome ( RLS ) symptom augmentation patient augmentation associate previous oral dopaminergic therapy . In addition , change treatment regimen use switch Neupro® evaluate .</brief_summary>
	<brief_title>Effect RLS Symptom Severity After Switching Neupro® Patients Who Previously Experienced Augmentation</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>The adult patient diagnosis moderate severe idiopathic Restless Leg Syndrome ( RLS ) The patient must experience augmentation due prior dopaminergic treatment The decision prescribe Neupro® make physician independently his/her decision enroll patient study Patient inform give ample time opportunity think his/her participation study give write inform data consent Patients diagnose secondary Restless Leg Syndrome ( RLS ) enrol observational study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Neupro®</keyword>
	<keyword>Augmentation</keyword>
	<keyword>Restless Legs Syndrome</keyword>
	<keyword>Moderate severe</keyword>
	<keyword>idiopathic</keyword>
	<keyword>adult</keyword>
</DOC>